L. Andrew (Drew) Thompson joined Fulcrum shortly after launch in summer 2016 and brings more than 20 years of experience in medicinal chemistry to the molecular sciences team. Drew joined Fulcrum from Bristol-Myers Squibb, where he led both early- and full-phase drug discovery programs in both neuroscience and genetically-defined diseases. Teams under Drew’s direction nominated two IND candidates including an allosteric modulator of gamma secretase targeting Alzheimer’s disease and an NR2B-selective NAM for treatment-resistant depression. He also helped establish the discovery chemistry platforms group and served on the leadership team while guiding chemistry efforts around phenotypic screening and target identification. At Fulcrum, Drew leads the molecular sciences effort spanning both preclinical discovery and clinical chemistry, manufacturing, and controls. Drew holds a bachelor’s in chemistry from the University of North Carolina at Chapel Hill and earned his Ph.D. from the University of California, Berkeley.